Episode

What Most Favored Nation Drug Pricing Would Mean for the US

Podcast
A Health Podyssey
Published
Apr 14, 2026
Duration seconds
1435
Processing state
not_requested
Canonical source
https://share.transistor.fm/s/364cdcdb
Audio
https://media.transistor.fm/364cdcdb/fd8f0aae.mp3
JSON
/v1/public/podcasts/a-health-podyssey-1366621/episodes/what-most-favored-nation-drug-pricing-would-mean-for-the-us
Markdown
/podcast/a-health-podyssey-1366621/what-most-favored-nation-drug-pricing-would-mean-for-the-us.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/a-health-podyssey-1366621/episodes/what-most-favored-nation-drug-pricing-would-mean-for-the-us/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/a-health-podyssey-1366621/what-most-favored-nation-drug-pricing-would-mean-for-the-us.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

Health Affairs ' Rob Lott interviews James Robinson of the University of California Berkeley about his recent paper exploring most favored nation drug pricing , weighing its feasibility, likely effects on drug launch prices, and implications for global pharmaceutical innovation and investment. Order the April 2026 issue of Health Affairs .